Australia Warns of Fake Rabies Vaccine in India; Indian Pharma Refutes Claims
Australia alerts on counterfeit Indian rabies vaccine; manufacturer denies, citing proactive action.
Photo by Mika Baumeister
त्वरित संशोधन
Australia issued an alert about counterfeit 'Abhayrab' anti-rabies vaccine.
The alert claims counterfeits circulating in India since November 2023.
Indian Immunologicals Limited (IIL) is the manufacturer.
IIL proactively identified batch #KA24014 in January 2023.
IIL notified Indian regulators and law enforcement about the counterfeit batch.
महत्वपूर्ण तिथियां
दृश्य सामग्री
Counterfeit Rabies Vaccine Incident: A Timeline
This timeline clarifies the sequence of events regarding the counterfeit 'Abhayrab' vaccine, highlighting the Indian manufacturer's proactive measures versus Australia's advisory, and placing it in the context of ongoing regulatory efforts.
The incident underscores the persistent challenge of counterfeit drugs in the global pharmaceutical supply chain, prompting enhanced vigilance and regulatory reforms in India and internationally. It highlights the critical need for robust quality control, supply chain integrity, and rapid information sharing in public health.
- Jan 2023Indian Immunologicals Ltd (IIL) proactively identifies a specific counterfeit batch (#KA24014) of 'Abhayrab' vaccine in India.
- Jan 2023IIL immediately notifies Indian drug regulators (CDSCO, State Drug Control) and law enforcement agencies about the counterfeit batch.
- Nov 2023Australia's health department issues an alert regarding counterfeit 'Abhayrab' vaccine in India, referencing the 2023 incident and urging travelers to check vaccination status.
- Late 2023 / Early 2024IIL strongly refutes the Australian advisory's 2023 reference, stating no other counterfeit batches found since Jan 2023, and requests a revision of the advisory.
- 2024-2025Continued national focus on strengthening pharmaceutical supply chain integrity, implementing advanced track & trace systems, and enhancing international regulatory cooperation to combat counterfeiting.
परीक्षा के दृष्टिकोण
Drug regulation and enforcement mechanisms in India (CDSCO, Drugs and Cosmetics Act)
Public health implications of counterfeit medicines, especially for critical vaccines like anti-rabies
Supply chain integrity and traceability in the pharmaceutical sector
International cooperation and information sharing in public health emergencies
Impact on India's image as a 'pharmacy of the world'
Role of technology in combating counterfeiting (e.g., serialization, blockchain)
विस्तृत सारांश देखें
सारांश
Australia's health department has issued a significant alert regarding the circulation of counterfeit 'Abhayrab' anti-rabies vaccine in India since November 2023, urging travelers to check their vaccination status. This raises serious public health concerns and questions about drug regulation. However, the Indian manufacturer, Indian Immunologicals Limited (IIL), has strongly refuted the advisory's 2023 reference, stating they proactively identified a specific counterfeit batch (#KA24014) in January 2023 and immediately notified Indian regulators and law enforcement.
IIL asserts that no other counterfeit batches have been found since and has requested Australia to revise its advisory. This incident highlights the critical importance of robust drug quality control, supply chain integrity, and international cooperation in public health, a topic frequently examined in UPSC GS2 (Health) and GS3 (Science & Technology, Economy).
पृष्ठभूमि
नवीनतम घटनाक्रम
बहुविकल्पीय प्रश्न (MCQ)
1. Consider the following statements regarding drug regulation in India: 1. The Central Drugs Standard Control Organisation (CDSCO) is responsible for the approval of new drugs and clinical trials in India. 2. The Drugs and Cosmetics Act, 1940, and Rules, 1945, primarily govern the manufacture, sale, and distribution of drugs in India. 3. State Drug Control Organizations are solely responsible for licensing of manufacturing establishments and sales premises, and for post-market surveillance. Which of the statements given above is/are correct?
- A.1 and 2 only
- B.2 and 3 only
- C.1 and 3 only
- D.1, 2 and 3
उत्तर देखें
सही उत्तर: A
Statement 1 is correct. CDSCO, headed by the Drugs Controller General of India (DCGI), is the national regulatory authority for Indian pharmaceuticals and medical devices, responsible for approval of new drugs, clinical trials, and setting standards. Statement 2 is correct. The Drugs and Cosmetics Act, 1940, and Rules, 1945, are the primary legislation governing drug regulation in India. Statement 3 is incorrect. While State Drug Control Organizations are responsible for licensing and post-market surveillance, CDSCO also plays a crucial role in coordinating with state authorities and in specific areas like import control and central licensing for certain categories of drugs. The responsibility is shared and coordinated, not solely with states for post-market surveillance.
2. In the context of Rabies and its prevention, which of the following statements is/are correct? 1. Rabies is a viral zoonotic disease that is almost always fatal once clinical symptoms appear. 2. India aims to eliminate dog-mediated rabies by 2030 through mass dog vaccination and post-exposure prophylaxis. 3. Post-exposure prophylaxis (PEP) for rabies involves only administering the rabies vaccine, not immunoglobulin. Select the correct answer using the code given below:
- A.1 only
- B.1 and 2 only
- C.2 and 3 only
- D.1, 2 and 3
उत्तर देखें
सही उत्तर: B
Statement 1 is correct. Rabies is caused by the rabies virus (Lyssavirus genus) and is transmitted to humans through the saliva of infected animals, typically via bites. It is indeed almost always fatal once clinical symptoms manifest. Statement 2 is correct. India launched the National Action Plan for Dog Mediated Rabies Elimination (NAPRE) by 2030, focusing on mass dog vaccination and provision of post-exposure prophylaxis (PEP). Statement 3 is incorrect. Post-exposure prophylaxis (PEP) for rabies typically involves both immediate wound washing and administration of rabies vaccine, and in severe cases (Category III exposures), Rabies Immunoglobulin (RIG) is also administered around the wound site to provide immediate passive immunity.
3. Which of the following measures can effectively contribute to combating the circulation of counterfeit drugs in India? 1. Implementing a robust track and trace system using serialization for pharmaceutical products. 2. Strengthening the capacity and infrastructure of drug testing laboratories across the country. 3. Enhancing international cooperation and intelligence sharing on counterfeit drug networks. 4. Mandating the use of only government-approved online pharmacies for drug procurement. Select the correct answer using the code given below:
- A.1, 2 and 3 only
- B.2, 3 and 4 only
- C.1, 3 and 4 only
- D.1, 2, 3 and 4
उत्तर देखें
सही उत्तर: A
Statement 1 is correct. A track and trace system, often using serialization (unique identification codes on each pack), allows for monitoring the drug's journey from manufacturer to consumer, making it harder for counterfeit products to enter the legitimate supply chain. Statement 2 is correct. Adequate and well-equipped drug testing laboratories are essential for quality control and detecting substandard or counterfeit drugs. Statement 3 is correct. Counterfeit drug networks often operate internationally, requiring cross-border intelligence sharing and coordinated enforcement actions. Statement 4 is incorrect. While regulating online pharmacies is important, mandating the use of *only* government-approved ones might be restrictive and not the sole solution. The focus should be on robust regulation and verification mechanisms for all pharmacies, including online ones, rather than a blanket mandate that might limit access or competition. The primary issue is verification and authenticity, not just the source being government-approved, as even approved channels can be infiltrated if not properly monitored.